ArthritoMabTM Arthritis-Inducing Antibody Cocktail. For the induction of arthritis in the Collagen Antibody Induced Arthritis (CAIA) model: a shorter, more synchronized alternative to the classic CIA model.
Collagen-induced arthritis (CIA) in mice is widely used as an experimental model for rheumatoid arthritis. Initial symptoms of inflammation in the CIA model occur at approximately day 21-24 with the model requiring 6-8 weeks to complete. The induction of disease is typically at 80% and varies from lab to lab and with the use of different collagen sources. The disease symptoms also appear at slightly different times in different animals, making therapeutic administration protocols more demanding technically. With the long study length, significant amounts of compounds are required. Furthermore, the lengthy study period also requires increased number of measurements and scoring periods, increasing the cost of the study further.
The above points illustrate some of the key issues in running a typical CIA model. The collagen antibody-induced model (CAIA) presents a real alternative to the CIA, significantly reducing the study duration and cost while increasing disease induction and synchronicity among individual animals.
Download whitepaper
Ovalbumin-induced asthma. Suitable efficacy models to aid in the discovery of novel treatments.
There is a major unmet need in the treatment of asthma which is growing in incidence and prevalence in industrialized countries. The prevalance of asthma has doubled in the Western world over the previous 20 years. In addition to the estimated 180,000 asthma related deaths per year, there is a sustantial economic burden due to lost school/work days and increased medical costs. The reasons for the increase in prevalance include increased exposure to indoor allergans or workplace sensitizers, more pollution and overuse of beta-2 agonists.
These facts highlight the need for novel treatments, which in turn require suitable efficacy models. This whitepaper reviews the ovalbumin-induced allergic asthma model and the variety of end-readouts available.
Download whitepaper
Experimental Allergic Encephalomyelitis (EAE). A myelin mediated disease model for the study of Multiple Sclerosis.
Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS). MS is one of the most common disabling neurological diseases in young adults. The main characteristics of this disease are focal areas of demyelination and inflammation, however the pathogenesis is unclear. The disease course is unpredictable and life-long, and affects women more commonly for unknown reasons. The etiology of the disease seems to be dependent on genetic and environmental factors. Several studies have suggested viral infections as a contributor of the disease.
This whitepaper will review 3 common EAE models for the study of Multiple Sclerosis.
Download whitepaper
Peripheral Nerve Injury Models of Neuropathic Pain. Understanding the mechanisms underlying neuropathic pain syndromes is crucial to the development of more effective therapies.
Neuropathic pain may arise from many different disease states and present with a variety of symptoms including shooting or burning pain, tingling, numbness and allodynia (pain in response to a normally innocuous stimulus). Clinically significant relief is often difficult to achieve, in part because conventional opiod therapy is typically less effective for neuropathic pain. Also, patients vary widely in their response to other types of analgesics. Understanding the mechanisms underlying neuropathic pain syndroms is crucial to the development of more effective therapies.
This whitepaper review two well-established peripheral nerve injury models of neuropathic pain: spinal nerve ligation (SNL) and chronic constriction injury (CCI).
Download whitepaper
A new animal model of Post-operative Pain. An optimal model for assessment of analgesic effect of various local treatment strategies such as implants, patches, medical devices and creams.
The under treatment of post operative pain has been recognized to delay patient recovery and discharge from the hospital. Despite recognition of the importance of efective pain control, up to 70% of patients still complain of moderate to severe pain post operatively. The most commonly used model to test the effect of new analgesic drugs in post operative pain is the Brennan model in rats. Although this model can provide good answers to systemic drugs, it is less suitable to testing local treatments such as implants, patches, medical devices and creams.
This whitepaper will review a model of post operative pain that MD Biosciences has developed. This model is unique and allows for the assessment of local and systemic therapies.
Download whitepaper
Discovering your immunomodulator's mode of action. Implementing a strategy that will put your preclinical drug discovery program on a systematic, efficient and focused progression.
Drug discovery and development is a long and time-consuming process. Pharmacuetical companies are under contant pressure to fill their product pipelines, decrease the number of late-phase failures and accelerate the drug to market process - all with less resources. The current approach to mode of action and target validation within drug discovery often fails to take advantage of the systems now available leading to a shotgun approach. This results in a dilema over target disease choice, a potentially longer discovery phase and progression into clinical stages is with limited mechanistic data, which can contribute to late-phase failures.
This whitepaper discusses an alternative approach offering the opportunity to avoid target disease dilema by allowing a more systematic, efficient and focused progression towards clinical studies.
Download whitepaper